RecruitingPhase 2NCT06485843

An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

An Open Label Phase IIb Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint


Sponsor

Ageless Biotech, Inc.

Enrollment

400 participants

Start Date

May 21, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.


Eligibility

Min Age: 35 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called OA-SYS for people with osteo arthritis knee and osteoarthritis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 35 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOA-SYS

OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.


Locations(1)

Orthopedic & Sports Medicine Institute of Las Vegas

Las Vegas, Nevada, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06485843


Related Trials